Deneysel akut iskemik inme modelinde edaravone ve askorbik asidin iskemi-reperfüzyon hasarı üzerine etkisi
[ X ]
Tarih
2023
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Kırıkkale Üniversitesi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Giriş ve Amaç: İskemik inme, tüm dünyada mortalite ve morbiditenin en önemli nedenlerinden biridir. İnme sonrası nöronal kaybın azaltılabilmesi için iskemi/reperfüzyon (I/R) hasarının ve serbest oksijen radikali (SOR) birikiminin önlenmesi çok önemlidir. Bu çalışmanın amacı akut iskemik inme (Aİİ) sonrası oluşan I/R hasarını önlemede farklı doz Edaravon ve Askorbik asit tedavilerinin biyokimyasal ve histopatolojik etkilerini araştırmaktır. Gereç ve Yöntem: Çalışmaya 40 adet Sprague-Dawley cinsi dişi rat dahil edildi. Ratlar rastgele seçimle her grupta 8'er tane olacak şekilde gruplandırıldı. Tüm gruplarda Aİİ'yi takiben I/R oluşturularak tedavi rejimi uygulandı. Grup DDE (Düşük Doz Edaravon): Edaravon 1 mg/kg, Grup YDE (Yüksek Doz Edaravon): Edaravon 5 mg/kg, Grup DDA (Düşük Doz Askorbik asit): Askorbik asit 100 mg/kg, Grup YDA (Yüksek Doz Askorbik asit): Askorbik asit 500 mg/kg tedavisi uygulanırken, Kontrol grubuna (Grup-K) herhangi bir tedavi uygulanmadı. Deney sonrası tüm ratlar sakrifiye edilerek kan ve beyin dokusu örnekleri alındı. Serum örneklerinden Malondialdehit (MDA) ve Nitrik oksit (NO) seviyesi, beyin dokusunda ise Hasarlı Nöron Yüzdesi (HNY) ölçümü yapıldı. Veriler SPSS 21.0 programı ile analiz edildi. p<0.05 değeri istatistiksel olarak anlamlı kabul edildi. Bulgular: Gruplar arasında en düşük serum MDA düzeyi, YDA tedavisi verilen gruptaydı. Serum MDA düzeyi bakımından DDA (0.80±0.13 nmol/ml) ve YDA (0.71±0.10 nmol/ml) tedavisi verilen gruplar ile Kontrol grubu (0.97±0.17 nmol/ml) arasında anlamlı farklılık saptandı (Sırasıyla p=0.040; 0.002). Farklı doz Edaravon tedavisi verilen gruplar ile Kontrol grubu arasında serum MDA düzeyi bakımından farklılık saptanmadı. Gruplar arasında en düşük serum NO düzeyi, YDA tedavisi verilen gruptaydı. Serum NO düzeyi bakımından YDA (63.31±11.94 µmol/l) tedavisi verilen grupla Kontrol grubu (80.01±14.74 µmol/l) arasında anlamlı istatistiksel farklılık saptandı (p=0.026). Diğer tedavi grupları ile Kontrol grubu arasında serum NO düzeyi bakımından farklılık saptanmadı. Gruplar arasında en düşük HNY, YDA tedavisi verilen gruptaydı. HNY düzeyi bakımından YDA (%39.1±0.1) tedavisi verilen grup ile Kontrol grubu (%42.6±0.2) arasında istatistiksel olarak anlamlı farklılık saptandı (p=0.002). Diğer tedavi grupları ile Kontrol grubu arasında HNY düzeyi bakımından anlamlı farklılık saptanmadı. Sonuç: I/R hasarının zararlı etkilerini önlemede farklı doz Edaravon tedavilerinin ve DDA tedavisinin başarısı sınırlıdır. YDA tedavisi hem biyokimyasal hem de histopatolojik düzeyde nöroprotektif etkiyi sağlamada en başarılı tedavi yöntemi olup, çalışmamızdaki tedavi protokolleri arasında I/R hasarını önlemede en iyi seçenektir.
Introduction and Purpose: Ischemic stroke is one of the most important causes of mortality and morbidity all over the world. It is very important to prevent ischemia/reperfusion (I/R) injury and free oxygen radical (SOR) accumulation in order to reduce neuronal loss after stroke. This study aims to investigate the biochemical and histopathological effects of different doses of Edaravone and Ascorbic acid treatments in preventing I/R injury after acute ischemic stroke (AIS). Materials and Methods: 40 Sprague-Dawley female rats were included in this study. The rats were randomly selected and 8 rats were placed in each group. In all groups, an I/R was created following AIS and a treatment plan was applied. The treatment list was as follows: Group LDE (Low Dose Edaravone): Edaravone 1mg/kg, Group HDE (High Dose Edaravone): Edaravone 5 mg/kg, Group LDA (Low Dose Ascorbic Acid): Ascorbic Acid 100 mg/kg, Group HDA (High Dose Ascorbic Acid): Ascorbic Acid 500 mg/kg. The control group (Group-C), however, received no treatment. After the experiment, all rats were sacrificed, blood and brain tissue samples were taken. Malondialdehyde (MDA) and Nitric oxide (NO) levels were assessed in serum samples, and the Percentage of Damaged Neurons (PDN) was measured in brain tissue. The data were analysed with the SPSS 21.0 program, p-value of <0.05 was considered statistically significant. Findings: The lowest serum MDA level among the groups was in Group HDA. In terms of serum MDA level, there was a statistically significant difference (p=0.040; 0.002, respectively) between Group LDA (0.80±0.13 nmol/ml) and HDA (0.71±0.10 nmol/ml) and the control group (0.97±0.17 nmol/ml). There was no difference in serum MDA level between the control group and the groups given different doses of Edaravone. The lowest serum NO level among the groups was in Group HDA. In terms of serum NO level, there was a statistically significant difference (p=0.026 µmol/l) between HDA (63.31±11.94 µmol/l) and the control group (80.01±14.74 µmol/l). There was no difference between the other treatment groups and the control group in terms of serum NO level. The lowest PDN among the groups was in Group HDA. In terms of PDN level, there was a statistically significant difference (p=0.002) between the control group (%42.6±0.2) and Group HDA (%39.1±0.1). No difference was found between the other treatment groups and the control group in terms of PDN level. Result: The success of different doses of Edaravone and LDA treatments in preventing the harmful effects of I/R injury is limited. In this study, HDA had the strongest neuroprotective effects at both biochemical and histopathological levels and was found to be the greatest choice for preventing I/R damage among the treatment protocols.
Introduction and Purpose: Ischemic stroke is one of the most important causes of mortality and morbidity all over the world. It is very important to prevent ischemia/reperfusion (I/R) injury and free oxygen radical (SOR) accumulation in order to reduce neuronal loss after stroke. This study aims to investigate the biochemical and histopathological effects of different doses of Edaravone and Ascorbic acid treatments in preventing I/R injury after acute ischemic stroke (AIS). Materials and Methods: 40 Sprague-Dawley female rats were included in this study. The rats were randomly selected and 8 rats were placed in each group. In all groups, an I/R was created following AIS and a treatment plan was applied. The treatment list was as follows: Group LDE (Low Dose Edaravone): Edaravone 1mg/kg, Group HDE (High Dose Edaravone): Edaravone 5 mg/kg, Group LDA (Low Dose Ascorbic Acid): Ascorbic Acid 100 mg/kg, Group HDA (High Dose Ascorbic Acid): Ascorbic Acid 500 mg/kg. The control group (Group-C), however, received no treatment. After the experiment, all rats were sacrificed, blood and brain tissue samples were taken. Malondialdehyde (MDA) and Nitric oxide (NO) levels were assessed in serum samples, and the Percentage of Damaged Neurons (PDN) was measured in brain tissue. The data were analysed with the SPSS 21.0 program, p-value of <0.05 was considered statistically significant. Findings: The lowest serum MDA level among the groups was in Group HDA. In terms of serum MDA level, there was a statistically significant difference (p=0.040; 0.002, respectively) between Group LDA (0.80±0.13 nmol/ml) and HDA (0.71±0.10 nmol/ml) and the control group (0.97±0.17 nmol/ml). There was no difference in serum MDA level between the control group and the groups given different doses of Edaravone. The lowest serum NO level among the groups was in Group HDA. In terms of serum NO level, there was a statistically significant difference (p=0.026 µmol/l) between HDA (63.31±11.94 µmol/l) and the control group (80.01±14.74 µmol/l). There was no difference between the other treatment groups and the control group in terms of serum NO level. The lowest PDN among the groups was in Group HDA. In terms of PDN level, there was a statistically significant difference (p=0.002) between the control group (%42.6±0.2) and Group HDA (%39.1±0.1). No difference was found between the other treatment groups and the control group in terms of PDN level. Result: The success of different doses of Edaravone and LDA treatments in preventing the harmful effects of I/R injury is limited. In this study, HDA had the strongest neuroprotective effects at both biochemical and histopathological levels and was found to be the greatest choice for preventing I/R damage among the treatment protocols.
Açıklama
Tıp Fakültesi, Acil Tıp Ana Bilim Dalı
Anahtar Kelimeler
Acil Tıp, Emergency Medicine, Nöroloji
